The bill proposes the enactment of several new sections within the Revised Code, specifically addressing individualized investigational treatments for patients suffering from life-threatening or severely debilitating illnesses. Key definitions are established, including "eligible facility," "eligible patient," and "individualized investigational treatment," which refers to treatments tailored to an individual's unique genetic profile. The bill outlines the conditions under which eligible patients may request such treatments, the responsibilities of manufacturers and facilities in providing these treatments, and the informed consent process required before treatment can commence.

Additionally, the bill stipulates that health benefit plans and governmental agencies may choose to cover costs associated with individualized investigational treatments, but it does not mandate such coverage. It also protects physicians from disciplinary actions based solely on their recommendations for these treatments and ensures that patients' heirs are not liable for debts related to treatments if the patient passes away. Importantly, the bill clarifies that it does not create a private cause of action against manufacturers or other entities involved in the care of patients receiving these investigational treatments, provided they comply with the outlined regulations.